Urotensin-II (U-II) has been considered as one of the most potent vasoactive peptides, although its physiological and pathophysiological role is still not finally resolved. Recent evidence suggests that it promotes angiogenic responses in endothelial cells, although the underlying signalling mechanisms are unclear. Reactive oxygen species derived from NADPH oxidases are major signalling molecules in the vasculature. Because NOX2 is functional in endothelial cells, we investigated the role of the NOX2-containing NADPH oxidase in U-II-induced angiogenesis and elucidated a possible contribution of hypoxia-inducible factor-1 (HIF-1), the master regulator of hypoxic angiogenesis, in the response to U-II. We found that U-II increases angiogenesis in vitro and in vivo, and these responses were prevented by antioxidants, NOX2 knockdown and in Nox2 -/-mice. In addition, U-II-induced angiogenesis was dependent on HIF-1. Interestingly, U-II increased NOX2 transcription involving HIF-1, and chromatin immunoprecipitation confirmed NOX2 as a target gene of HIF-1. In support, NOX2 levels were greatly diminished in U-II-stimulated isolated vessels derived from mice deficient in endothelial HIF-1. Conversely, reactive oxygen species derived from NOX2 were required for U-II activation of HIF and upregulation of HIF-1. In line with this, U-II-induced upregulation of HIF-1 was absent in Nox2 -/-vessels. Collectively, these findings identified HIF-1 and NOX2 as partners acting in concert to promote angiogenesis in response to U-II. Because U-II has been found to be elevated in cardiovascular disorders and in tumour tissues, this feed-forward mechanism could be an interesting anti-angiogenic therapeutic option in these disorders.
Introduction
Angiogenesis plays a major physiological role during embryonic development and later, in adult life, in several physiological and pathophysiological conditions, including cancer, inflammation and various cardiovascular diseases. The angiogenic process includes the formation of capillaries from pre-existing vessels, i.e. capillary and postcapillary venules that develop as a result of endothelial sprouting or intussusceptive microvascular growth (Folkman, 2003) . A major stimulus of angiogenesis, particularly in cancer and inflammation, is hypoxia. Within this setting the family of hypoxia-inducible transcription factors (HIFs) plays a pivotal role (Coulon et al., 2010) . These heterodimers consist of an oxygen-sensitive a-subunit, and a barely regulated b-subunit. HIF-1a is the most abundant of the regulated subunits of this family. It is unstable under normoxia because of its interaction with the E3 ubiquitin ligase pVHL, which primes it for proteasomal degradation (Semenza, 2001) . Under hypoxia, this interaction ceases thus stabilizing HIF-1a and allowing its transcriptional activity (Ratcliffe et al., 1998; Semenza, 2000; Wenger et al., 2005) .
In recent years, it has been shown that HIF-1a is also responsive to a variety of growth factors, procoagulant factors, hormones and cytokines even under normoxic conditions (Dery et al., 2005; Gorlach and Kietzmann, 2007) . Because several of these factors can also promote angiogenesis, activation of HIF by these factors could contribute to the proangiogenic response not only under hypoxic but also under normoxic conditions. Recent evidence suggests that in addition to proangiogenic growth factors such as VEGF and PDGF, several peptide hormones that have known functions in controlling vascular tone, including angiotensin-II and endothelin-1, are able to promote endothelial proliferative responses (Ribatti et al., 2007) .
One of the most potent vasoactive peptides is urotensin-II (U-II; also known as urotensin-2), which was originally isolated from the fish urophysis. Human U-II is a cyclic 11-amino-acid peptide that has been identified as an endogenous ligand of the orphan receptor GPR14, also named urotensin-II receptor (Ames et al., 1999; Maguire and Davenport, 2002) . U-II and GPR14 are expressed in many organs and in different vascular beds in endothelial and smooth muscle cells. They have been associated with several cardiovascular pathologies including atherosclerosis and pulmonary vascular remodelling Watanabe et al., 2009 ). Interestingly, U-II and its receptor have also been found in several tumour cell lines (Yoshimoto et al., 2004) . Although its importance is yet unclear in the tumour setting, U-II has been shown to exert a marked mitogenic and proliferative action on vascular cells (Djordjevic et al., 2005; Spinazzi et al., 2006) so that it might also play an important role in controlling tumor adaptation to the microenvironment and survival by contributing to angiogenesis. However, the molecular mechanisms underlying activation of endothelial cells by U-II are not clear.
Reactive oxygen species (ROS) have been identified as important signalling molecules in many cell types including endothelial cells, and have been associated with endothelial cell proliferation and new vessel formation in response to growth factors including VEGF and PDGF (Maulik, 2002) . A major source of vascular ROS are NADPH oxidases (Lassegue and Griendling, 2010) . This family of multiprotein enzymes contains one of five membrane-bound catalytic NOX proteins (termed NOX1 to NOX5) and the p22phox subunit comprising the cytochrome b 558. The originally identified NOX2-containing enzyme (formerly termed gp91phox), as well as some other family members, include additional cytosolic regulatory subunits, among them the GTPase Rac. These subunits are required for activation of the leukocyte enzyme to generate superoxide and consecutive ROS in the innate immune response (El-Benna et al., 2008) .
Interestingly, NOX2 has also been identified as a major source of ROS in endothelial cells and has been related to the control of vascular tone and angiogenesis (Gorlach et al., 2000; UshioFukai et al., 2002) . Subsequently, other NOX enzymes, including NOX4 and NOX5 have also been found to contribute to ROS generation in these cells (Petry et al., 2006; BelAiba et al., 2007) although the exact importance of this apparent redundancy remains unclear.
Given the importance of NOX2 in endothelial function we investigated the role of this enzyme in the angiogenic response towards U-II, and identified HIF-1a as a central element promoting a feed-forward mechanism of ROS-mediated angiogenesis by U-II.
Results

Urotensin-II stimulates angiogenesis through GPR14
In a first step we investigated the role of U-II in the angiogenic response of human endothelial cells using a Matrigel tube formation assay. Exposure to U-II significantly induced the formation of capillary-like structures by 1.560.1 fold (P,0.05). However, treatment with the GPR14 antagonist urantide completely prevented this response (Fig. 1A) . Similarly, depletion of GPR14 by shRNA significantly decreased U-II-induced endothelial tube formation (Fig. 1B ) from 1.760.04 to 1.260.1 fold (P,0.05) indicating that U-II acts through its receptor to promote an angiogenic response.
Because angiogenesis in vivo typically initiates from the venous side of the vascular bed (Folkman, 2003) we cultured mouse vena cava explants in a collagen matrix and monitored angiogenic outgrowth. Exposure to U-II increased vessel sprouting, whereas pretreatment with urantide reduced this response (Fig. 1C ). Subsequently, we used an in vivo model to evaluate the involvement of U-II and GPR14 in angiogenesis. To this end, Matrigel plugs containing U-II in the presence or absence of urantide were injected subcutaneously into mice and invasion of vessels into the plug was assessed after 7 days by immunohistochemistry using an antibody against CD31 (Fig. 1D) . Compared with control plugs, vessel invasion was markedly increased into U-II-containing plugs. However, this response was not observed with Matrigel plugs also containing urantide. Because U-II also stimulated endothelial cell proliferation, as measured by BrdU incorporation, and urantide diminished this response (data not shown), our data clearly show (A) Human umbilical vein endothelial cells (HUVEC) were plated on growthfactor-reduced Matrigel and stimulated with U-II (urotensin-II; 100 nM) for 4 hours in the presence or absence of the U-II receptor (GPR14) antagonist urantide (100 nM), to allow for the formation of capillary-like structures. (B) HUVEC were transfected with vectors encoding shRNA against GPR14 (shGPR14) or control shRNA (shCtr) and plated on Matrigel for 4 hours to allow for the formation of capillary-like structures. (C) Vena cava explants were cultured in collagen gels and stimulated with U-II with or without urantide. After 4 days the cultures were examined for the vessel sprouting. (D) Growth-factor-reduced Matrigel was mixed with U-II and/or urantide. The Matrigel mixture was injected subcutaneously into mice (C5BL6, 6-week-old males). Matrigel plugs were excised 1 week after injection, fixed in formalin and embedded in paraffin. The formation of capillary-like structures was assessed in sections by CD31 staining. All images are representative of at least three independent experiments. that U-II stimulates angiogenesis in vitro and in vivo by acting through its receptor GPR14.
NOX2-derived ROS are involved in angiogenesis
Because ROS have been previously described to promote angiogenesis, we determined their contribution to U-II-induced angiogenesis. First, we measured ROS levels in the presence of U-II in endothelial cells by dihydroethidium (DHE) fluorescence ( Fig. 2A,B ). U-II was able to induce ROS formation, and this response was diminished by urantide or depletion of GPR14, indicating that U-II increases ROS levels in endothelial cells by acting through its receptor. Next, endothelial cells submitted to a Matrigel assay were treated with the antioxidant N-acetylcysteine (NAC) and then exposed to U-II. Compared with controls NAC completely prevented U-II-induced tube formation, suggesting the involvement of ROS in this response (Fig. 2C) .
The NOX2-containing NADPH oxidase has been identified as an important source of ROS in endothelial cells, so we tested the involvement of NOX2 in U-II-induced angiogenesis. To this end, NOX2 was depleted by shRNA in endothelial cells. Compared with cells transfected with control shRNA, U-II-stimulated tube formation in the Matrigel assay was completely abolished in NOX2-depleted cells (Fig. 2D ). In line with this, U-II was not able to increase ROS formation in NOX2-depleted endothelial cells (Fig. 2B) .
To further test the functional relevance of NOX2 in the angiogenic response, we monitored vascular outgrowth from vena cava explants derived from Nox2 knockout (Nox2 -/-) and wild-type mice. Upon stimulation with U-II, vessel sprouting was decreased in Nox2 -/-explants ( Fig. 2E ). Subsequently, invasion of new vessels into Matrigel plugs containing U-II was diminished in Nox2 -/-mice compared with wild-type mice (Fig. 2F) , confirming that U-II promotes angiogenesis through NOX2 also in vivo.
HIF-1a mediates U-II-induced NOX2 expression and activity
We then investigated, whether NOX2 expression is regulated by U-II in endothelial cells. Indeed, NOX2 mRNA levels were rapidly elevated 2 hours after U-II stimulation (Fig. 3A) followed by increased NOX2 protein levels. Treatment with actinomycin D before exposure to U-II prevented U-II induction of NOX2 (Fig. 3B ), suggesting that a transcriptional mechanism contributes to NOX2 upregulation by U-II.
Because the transcription factor HIF-1 plays an important role in controlling angiogenesis under hypoxia, we determined its involvement in the endothelial response to U-II. Interestingly, ) or wildtype (WT) mice were cultured in collagen gels and exposed to U-II. After 4 days the cultures were examined for the vessel sprouting. (F) Matrigel was mixed with U-II and/or urantide. The Matrigel mixture was injected subcutaneously into WT and Nox2 -/-mice. Matrigel plugs were excised 1 week after injection, fixed in formalin and embedded in paraffin. The formation of capillary-like structures was assessed in sections by CD31 staining. All images are representative of at least three independent experiments. U-II rapidly increased the levels of HIF-1a within 1 hour of stimulation (Fig. 4A ). Subsequently, depletion of HIF-1a by shRNA diminished U-II-induced NOX2 mRNA and protein levels, whereas overexpression of HIF-1a increased NOX2 expression, indicating a tight link between HIF-1a and NOX2 (Fig. 4B,C) . To determine whether HIF-1a upregulates NOX2 also in vivo, venae cavae and lungs were isolated from mice with a specific deletion of HIF-1a in endothelial cells (Hif1a EC, -/-, in Fig. 4D and supplementary material Fig. S1 ) or from control mice (Hif1a EC, +/+) and exposed to U-II for 1 day or left untreated ( Fig. 4D) . Although U-II stimulation increased NOX2 protein levels in wild-type tissues, NOX2 levels were reduced in tissues deficient in endothelial HIF-1a even in the presence of U-II, indicating that HIF-1a mediates NOX2 expression also in vivo. In fact, bioinformatic analysis of the NOX2 promoter (MatInspector, Genomatix, Munich, Germany) revealed the presence of a putative hypoxiaresponsive element (HRE) at -5767 to -5771 bp, which is known to bind HIFs. We thus performed chromatin immunoprecipitation using an antibody against HIF-1a and analysed the precipitates by real-time PCR with primers amplifying the region of the NOX2 promoter containing the HRE or an intronic sequence of actin not containing an HRE. Compared with control conditions U-II enhanced binding of HIF1a to the NOX2 promoter, whereas this was not the case for the actin gene (Fig. 4E, supplementary material Fig. S2 ). Finally, to evaluate the functional consequences of HIF-1a regulation of NOX2, we overexpressed HIF-1a and determined ROS levels. Compared with control cells, ROS levels were enhanced in HIF-1a-overexpressing endothelial cells (Fig. 4F) . However, depletion of NOX2 in HIF-1a-overexpressing cells abrogated ROS generation, indicating that HIF-1a increases ROS production through its target gene NOX2. In line with this, depletion of HIF-1a completely prevented U-II-induced tube formation (Fig. 4G ).
NOX2 is involved in the upregulation and activation of HIF-1a
Because ROS have previously been shown to be part of the signalling cascades regulating HIF-1a under non-hypoxic conditions, we investigated whether regulation of HIF-1a by U-II is also mediated by ROS. When endothelial cells were treated with NAC, HIF-1a induction by U-II was diminished (Fig. 5A) . Subsequently, depletion of NOX2 prevented HIF-1a protein upregulation and HIF activation by U-II (Fig. 5B,C) , indicating that NOX2 is not only a HIF-1 target gene, but NOX2-dependent ROS are also required for controlling HIF-1a levels by U-II. These findings suggested a positive feedback loop whereby NOX2 induces HIF-1a and vice versa. In line with this proposal, HIF-1a was absent in lung tissue and venae cavae isolated from Nox2 -/-mice even in the presence of U-II (Fig. 5D ). Additionally, immunohistochemical analysis of the Matrigel plugs implanted into wild-type or Nox2 -/-mice detected increased HIF-1a staining in U-II-stimulated control plugs, but not in plugs from Nox2 -/-mice (Fig. 5E ).
Discussion
In this study we demonstrated that U-II is a potent stimulus of angiogenesis in vitro and in vivo and identified HIF-1a and its target NOX2 as crucial elements mediating this ROS-dependent response, because (1) U-II induced angiogenesis that was dependent on ROS, NOX2 and HIF-1a; (2) U-II increased NOX2 transcription that was dependent on HIF-1a in vitro and in vivo; (3) U-II upregulated HIF-1a that was dependent on ROS and NOX2; and (4) HIF-1a induced ROS generation through NOX2. Recent evidence suggested that several peptide hormones including angiotensin-II and endothelin-1 not only have vasoactive functions, but can also modulate proliferation and synthesis properties of vascular cells. Here we clearly demonstrated that the vasoactive peptide U-II is a strong activator of angiogenesis not only in vitro as has been indicated previously (Spinazzi et al., 2006) but also in vivo, and provided evidence that U-II acts through its receptor GPR14. Our study identified for the first time a ROS-dependent mechanism underlying the angiogenic response towards U-II and its receptor. We identified a NOX2-containing NADPH oxidase as a source of ROS: NOX2 depletion not only diminished U-II-induced ROS formation, but also prevented the angiogenic response towards U-II. This response was confirmed ex vivo in vena cava explants derived from Nox2 -/-mice that were found to be resistant to the proangiogenic action of U-II, as well as in vivo, Fig. 3 . U-II increases mRNA and protein levels of NOX2. (A) HMEC-1 cells were stimulated with U-II (100 nM) for different times and mRNA and proteins were isolated. Northern blot analysis was performed using a specific probe for NOX2. Ethidium bromide staining for 18S RNA served as a loading control. Western blot analyses were performed using an antibody against NOX2. Actin served as loading control. Data are presented as percentage change relative to the control (100%; n53, *P,0.05 versus control). (B) HUVECs were pretreated with actinomycin D (ActD; 5 mM) for 30 minutes and stimulated with U-II for 4 hours. NOX2 protein levels were detected by western blotting. Actin served as a loading control. Blots are representative of three independent experiments.
in Nox2 -/-mice in which the angiogenic response towards U-II was blunted. Although this is the first report demonstrating an involvement of NOX2 in the angiogenic response to U-II, our study is supported by previous reports indicating that NOX2 is important in the regulation of angiogenesis in response to VEGF, to hindlimb ischemia (Ushio-Fukai et al., 2002; Tojo et al., 2005) or to stimulation with thrombin under non-ischemic conditions (Diebold et al., 2009) .
Although ROS-dependent angiogenesis by growth factors has been mainly attributed to activation of NOX2 through Rac1 (Ushio-Fukai et al., 2002) , our study shows that in addition to rapid stimulation of ROS generation by U-II-induced Rac1 activation (data not shown), U-II also acts on a prolonged basis by inducing NOX2 expression by a transcriptional mechanism.
Importantly, this response was mediated by the transcription factor HIF-1, the major regulatory element in the control of angiogenesis under hypoxic conditions. In fact, induction of NOX2 was completely absent in HIF-1a-depleted human endothelial cells as well as in vascular and lung tissue derived from mice deficient in endothelial HIF-1a. Importantly, using chromatin immunoprecipitation we could demonstrate direct binding of HIF-1a to the distal NOX2 promoter, identifying NOX2 as a true HIF-1 target gene. Of note, our previous data from smooth muscle cells showed that NOX4 also is a direct Fig. 4 . HIF-1a mediates U-II-induced NOX2 expression and activity. (A) HMEC-1 cells were stimulated with U-II (100 nM) for different times. Western blot analyses were performed using an antibody against HIF-1a. Actin served as a loading control. (B,C) HMEC-1 cells were transfected with vectors encoding HIF-1a (HIF1a), control shRNA (shCtr) or shRNA against HIF-1a (shHIF1) and stimulated with U-II for 4 hours. (B) Northern blots were performed using specific probes for NOX2 or HIF1a. Ethidium bromide staining for 18S RNA served as a loading control. (C) Western blot analyses were performed using antibodies against NOX2 or HIF-1a. Actin was used as loading control. All blots are representative of three independent experiments. (D) Lung tissue and venae cavae were isolated from endothelial-cell-specific HIF-1a knockout (Hif1a EC, -/-) or control mice (Hif1a EC, +/+). Tissues were stimulated ex vivo with U-II for 24 hours or left untreated, and protein was isolated. Western blot analyses were performed with antibodies against NOX2, HIF-1a or actin. Blots are representative of three independent experiments. (E) HMEC-1 cells were stimulated with U-II for 4 hours and chromatin immunoprecipitation was performed with an antibody against HIF-1a. qPCR was performed using specific primers to amplify a fragment of the NOX2 promoter containing a putative HIF binding site. Quantification is shown in promille to chromatin input after background IgG subtraction (n53, *P,0.05 versus Ctr). (F) HMEC-1 cells were cotransfected with vectors coding for HIF-1a (HIF1a) or control vector and vectors coding for shRNA against NOX2 (shNOX2) or control shRNA (shCtr). ROS levels were evaluated by DHE fluorescence. ROS levels of cells transfected with control vectors were set to 100% (n53; *P,0.05 versus control or # P,0.05 versus cells overexpressing HIF1a). (G) Human umbilical vein endothelial cells (HUVEC) were transfected with vectors encoding shRNA against HIF-1a (shHIF1a) or control shRNA (shCtr) and plated on Matrigel. Tube formation was assessed 4 hours after stimulation with U-II (100 nM). The images are representative of three independent experiments. target gene of HIF-1 under hypoxic conditions (Diebold et al., 2010a) and is also upregulated by U-II (Djordjevic et al., 2005) . Similarly, U-II increased NOX4 levels in endothelial cells (supplementary material Fig. S3 ). In line with our previous reports that NOX4 contributes to endothelial proliferation (Petry et al., 2006) , we also observed a contribution of NOX4 to U-IIinduced angiogenesis (supplementary material Fig. S4 ) and ROS production (supplementary material Fig. S5 ). However, depletion of NOX4 was less effective in reducing ROS levels by U-II than depletion of NOX2, and knockdown of NOX2 and NOX4 did not further decrease ROS levels compared with NOX2 knockdown alone (supplementary material Fig. S5 ). This study, thus, clearly supports the importance of NOX2 in ROS generation and the angiogenic response towards U-II.
Together with our finding that the activator of NOX2, Rac1, is also transcriptionally regulated by HIF-1 (Diebold et al., 2010c) , we consider there to be a close interaction between the HIF pathway and NADPH oxidases in different vascular cells. In fact, overexpression of HIF-1a was sufficient to induce ROS generation in endothelial cells and also in smooth muscle cells (Diebold et al., 2010a) , but this response was prevented by depletion of NOX2 or NOX4, respectively. Because upregulation of NOX subunits is supposed to maintain elevated levels of ROS over a prolonged period of time, our findings suggest that HIF-1a takes centre stage in regulating NOX subunits not only under hypoxic, but also under non-hypoxic conditions associated with increased levels of pathogenetically relevant factors such as U-II. Interestingly, U-II has been also found in tumour cells (Takahashi et al., 2003) , and our own findings showed that tumour cells exposed to hypoxia are able to secret U-II (data not shown). Because U-II induced HIF-1a-and NOX2-dependent angiogenesis, our findings could provide a new mechanism of regulating tumour angiogenesis.
Interestingly, within this setting, we could show that HIF activity and HIF-1a protein levels are rapidly upregulated by U-II, and this response was dependent on ROS. Consequently, HIF1a could not be upregulated by U-II in NOX2-depleted endothelial cells or in vascular or lung tissue from Nox2 -/-mice, supporting the notion that NOX2 is of primary importance for induction and maintenance of endothelial HIF-1a protein, which in turn promotes NOX2 transcriptional upregulation. In addition to earlier studies that showed that p22phox and Rac1, which are important for NOX2 function, regulate HIF-1a levels in response to thrombin (Gorlach et al., 2001 ) and several other stimuli (BelAiba et al., 2004; Dery et al., 2005; Gorlach and Kietzmann, 2007) , more recent studies provided evidence that NOX4-dependent ROS generation enhances HIF-1a and HIF-2a levels Diebold et al., 2010b) . Our study now adds NOX2 to the sources of ROS regulating HIF-a levels and provides functional proof of the importance of NADPHoxidase-derived ROS for maintaining HIF-a levels under nonhypoxic conditions, which occurs by either stabilizing HIF-a by impairing interaction with the ubiquitin 3 ligase pVHL, or by transcriptional upregulation of HIF-1a by an NFkB-dependent pathway Diebold et al., 2010b) .
Collectively, our data suggest a model in which a rapid increase in ROS generation as a result of U-II activation of or wild-type (WT) mice were stimulated with U-II for 24 hours, and HIF-1a and NOX2 protein levels were assessed by western blot analysis using antibodies against HIF-1a and NOX2. Actin staining served as loading control. The blots are representative of three independent experiments. (E) Matrigel was mixed with U-II and injected subcutaneously into Nox2 -/-or WT mice. Matrigel plugs were excised 1 week after injection, fixed with formalin and embedded in paraffin. Immunohistochemistry was performed with an antibody against HIF-1a. All images are representative of at least three independent experiments. NOX2 elevates HIF-1a levels leading to HIF-1a binding to the NOX2 promoter and enhanced transcription of NOX2. Higher levels of ROS increase the angiogenic response towards U-II and also help to keep HIF-1a levels elevated for a more prolonged time period (Fig. 6) . One might speculate that this positivefeedback loop is limited by a mechanism similar to the situation under hypoxia (del Peso et al., 2003) : increased HIF-1a levels would over time upregulate the levels of prolyl hydroxylases known to be HIF target genes. This would then in turn limit further increases in HIF-1a and subsequently in NOX2.
Our results provide support for the importance of the crosstalk between NADPH oxidases and HIF proteins in a variety of conditions associated with enhanced angiogenesis under nonhypoxic conditions.
Materials and Methods
Materials
Urotensin-II was from Bachem (Weil am Rhein, Germany), urantide was from International peptides (Louiseville, KY). All other reagents were from Sigma (Munich, Germany) unless otherwise stated.
Cell culture
Human umbilical endothelial cells (HUVEC) were from Lonza (Wuppertal, Germany), cultured in the medium provided as recommended, and used up to passage 4. Human microvascular endothelial cells (HMEC-1) were purchased from CDC (Atlanta, GA) and grown in MCDB 131 medium (Gibco, Karlsruhe, Germany) with 10 mM Mg 2+ as recommended, containing 10% fetal calf serum (PAN Biotech, Aidenbach, Germany), 100 IU/ml penicillin (Gibco), 100 mg/ml streptomycin (Gibco), 1 mg/ml hydrocortisone, 2 mM L-glutamine (Gibco) and 10 ng/ml EGF. The human embryonic kidney cell line HEK293 (ATCC CRL-1573) was cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco) with 1 g/l glucose, 10% fetal calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin. All cells were grown at 37˚C in 5% CO 2 and passaged twice a week. (Pollock et al., 1995) . Mice with endothelial cell-specific inactivation of HIF-1a were generated by cross-breeding Tie2-Cre transgenic mice (B6.Cg-Tg(Tek-cre)12Flv/J; Jackson Laboratories) with Hif1a +f/+f mice homozygous for the Hif1a allele with exon 2 flanked by loxP sites (B6.129-Hif1a tm3Rsjo /J; Jackson Laboratories) (Ryan et al., 2000) . All mice were of a genetic C57BL/6 background. In all experiments, littermates from the same breeding pair were used as controls. For genotyping, genomic DNA was isolated from the tail, an intact aorta or an aorta with manually removed endothelium, using phenol-chloroform extraction according to standard protocols. Hif1a 1-lox and 2-lox alleles were detected with the following primers: forward 1: 59-TTGGGGATGAAAACATCTGC-39; forward 2: 59-GCAGTTAAGAGCACTAG-TTG-39; and reverse: 59-GGAGCTATCTCTCTAGACC-39. The 2-lox allele (floxed allele) was identified as a 260 bp band and the 1-lox allele (Hif1a deletion) as a 270 bp band. Tie2-Cre tg was detected using primers within the Tie2 promoter and Cre-coding region (forward: 59-CCCTGTGCTCAGACAGAAAT-GAGA-39; reverse: 59-CGCATAACCAGTGAAACAGCATTGC-39). All animal experiments were approved by the Regierung von Oberbayern.
Plasmids and transfections
The vectors encoding shRNA against HIF-1a, NOX2, NOX4 or a nonspecific random sequence (shCtr) have been previously described (Petry et al., 2006; Bonello et al., 2007; Diebold et al., 2010a) . Specific short hairpin RNA encoding for a 19mer siRNA (59-GTGCGGTGGCCTCCATGTA-39) against GPR14 (siGPR14) was created using the siRNATarget Designer and the siSTRIKE U6 Hairpin Cloning System (Promega, Mannheim, Germany). All constructs were confirmed by DNA sequencing. The plasmid encoding V5-tagged HIF-1a was kindly provided by Thomas Kietzmann, Oulu, Finland (Klein et al., 2008) . The construct pGl3EPOHRE-Luc containing three HIF-binding sites in front of the SV40 promoter has been described previously . Cells were plated to a density of 70% and cultured for 24 hours. Transfections were performed using FuGene reagent (Roche, Mannheim, Germany) as described (Diebold et al., 2009) . Transfection efficiency was on average 40%.
Northern blot analysis
Total RNA from endothelial cells was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RNA (10-15 mg) was separated on 1.3% agarose gels, transferred to nylon membranes, and cross-linked by UV irradiation. Northern hybridizations were carried out with digoxigenin-labelled antisense RNA probes for NOX2 and HIF1A. Detection was performed after incubation with a digoxigenin antibody conjugated to alkaline phosphatase using the chemiluminescent substrate CDPStar (Roche). Loading of equal amounts of RNA was confirmed by ethidium bromide staining of 18S RNA.
Western blot analysis
Western blot analysis was performed as described previously (Petry et al., 2006) . Briefly, 50 mg of isolated proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. After blocking for 1 hour in TBS (Tris-buffered saline) containing 5% milk and 0.3% Tween 20 (TBS-T), membranes were incubated overnight at 4˚C with a monoclonal antibody against NOX2 (mAb 48, kindly provided by Dirk Roos, Amsterdam), monoclonal or polyclonal antibodies against HIF-1a (Transduction Laboratories, Heidelberg, Germany or Abcam, Cambridge, UK), or polyclonal antibodies against GPR14 (Santa Cruz, Heidelberg, Germany) or NOX4 (Diebold et al., 2010a) . After incubation with a horseradishperoxidase-conjugated secondary antibody (Calbiochem, Darmstadt, Germany) for 1 hour, proteins were visualized by luminol-enhanced chemiluminescence. Loading of equal amounts of proteins was confirmed by reprobing the membranes with an actin antibody (Santa Cruz, Heidelberg, Germany). Blots were scanned and analysed using GelDoc software (Bio-Rad, Munich, Germany).
Chromatin Immunoprecipitation
Confluent endothelial cells were serum starved for 16 hours, and exposed to U-II for 4 hours. Cells were fixed with formaldehyde, lysed and sonicated to obtain DNA fragments of approximately 500-1000 base pairs. Chromatin was then precipitated with an HIF-1a antibody (Abcam) overnight at 4˚C. qPCR was performed with primers for the NOX2 promoter (forward: 59-CGGGTGCT-GGAGAGGATGTGGA-39; reverse: 59-TCCCTGAGGAATCGCCACACTGA-39) flanking the potential HIF-1 binding site (antisense sequence: aaacatACGTGtgc, HRE at -5767 to -5771 bp) using a Rotorgene 6000 (Corbett, Wasserburg, Germany). As a negative control for nonspecific binding and precipitation, qPCR using primers amplifying a region of the third intron of b-actin (gene ID: 60) without a putative HRE (59-ACGTG-39) was performed (forward: 59-AACACTGGCTCGTGTGACAA-39; reverse: 59-AAAGTGCAAAGAACAC- Fig. 6 . Scheme. The scheme summarizes the pathway described: urotensin-II binds to its receptor GPR14, leading to ROS generation from a NOX2-containing NADPH oxidase. This results in upregulation of the hypoxiainducible transcription factor HIF-1a. Active HIF-1 binds to the NOX2 promoter resulting in increased NOX2 expression. Enhanced NOX2 levels result in increased ROS generation, which fuels this feed-forward loop leading to increased angiogenesis. GGCT-39). As a background control, chromatin immunoprecipitation was performed using standard IgG (Santa Cruz). Statistical analysis was performed using a standard curve of the input, and increased HIF-1a binding to chromatin is presented after background (IgG) subtraction as relative amount of the input used. In addition, a non-quantitative PCR was performed in a standard Thermocycler (Applied Biosystems, Invitrogen, Germany).
Measurement of ROS production
ROS generation was detected using the fluoroprobe dihydroethidium (DHE, Invitrogen, Karlsruhe, Germany) in a microplate reader (Tecan, Crailsheim, Germany), as previously described (Diebold et al., 2009 ).
In vitro Matrigel assay
Endothelial cells were seeded at a density of 25,000 cells per well on a 96-well plate mounted with growth-factor-reduced Matrigel (BD Biosciences, Heidelberg, Germany). Cells were then incubated for 24 hours at 37˚C and stained using DiffQuick (Baxter Diagnostics, Duedingen, Switzerland). The formation of closed capillary-like structures was assessed by light microscopy (Olympus, Hamburg, Germany) using the Openlab Modular Software for Scientific Imaging (Improvision, Heidelberg, Germany) and was quantified using ImageJ software (Wright Cell Imaging Facility, Toronto, Canada) as described previously (Diebold et al., 2009 ).
Ex vivo vessel ring sprouting assay 6-week-old male mice (C5BL6, or Nox2 -/-mice) were killed and the vena cava was excised. The vena cava was transferred into a dish with sterile PBS. After removing the fibroadipose tissue, vessels were sectioned into 1-1.5 mm long cross sections, placed on Matrigel-coated wells (BD Bioscience; 100 ml/well) and incubated at 37˚C for 20 minutes. Thereafter the rings were incubated with 500 ml DMEM medium. The cultures were kept at 37˚C in a humidified environment for 4 days. Every second day vessel sprouting was assessed by light microscopy (Olympus) using the Openlab Modular Software for Scientific Imaging (Improvision) and was quantified using ImageJ software (Wright Cell Imaging Facility). All animal experiments were approved by Regierung von Oberbayern.
Matrigel plug assay
Growth-factor-reduced Matrigel (BD Biosciences) was mixed with U-II (100 nM) and/or urantide (100 nM). The Matrigel mixture was subcutaneously injected into 6-week-old male mice (C5BL6 or Nox2 -/-). Matrigel plugs were excised 7 days after injection, formalin-fixed and paraffin embedded to prepare sections for histochemical staining. The formation of capillary-like structures was assessed by staining with an antibody against CD31 (DAKO, Glostrup, DK) in a 1:50 dilution. HIF-1a levels were determined by staining with an antibody against HIF-1a (Abcam) in a 1:100 dilution. 1% BSA was used as negative control. All animal experiments were approved by Regierung von Oberbayern.
Statistical analysis
Values are presented as means 6 standard deviation (s.d.). Results were compared by ANOVA for repeated measurements followed by Student-Newman-Keuls t-test. P,0.05 was considered statistically significant. Genomic DNA was isolated from tail or from aortae from wildtype (ECHif1α+/+) or HIF-1α-deficient (ECHif1α-/-) mice with (+EC) or without (-EC) endothelium. PCR was performed corresponding to the floxed Hif1α allele (2-Lox), the exon 2 deleted Hif1α allele (1-Lox) ) or the Tie2Cre transgene (Tie2cre).
1-Lox
